Apolipoprotein A1
The Apolipoprotein A1 test measures the principal protein of HDL, providing a direct count of HDL particles and a marker of reverse cholesterol transport capacity. Low Apo A1 predicts cardiovascular risk independently of HDL-cholesterol, particularly in metabolic syndrome and diabetes; the ApoB:ApoA1 ratio quantifies atherogenic lipoprotein balance and often outperforms traditional lipid ratios.
1
Biomarkers
Blood (serum)
Sample
2–3 business days
Turnaround
Preferred
Fasting
What is the Apo A1 test?
The Apolipoprotein A1 test quantifies the major protein constituent of HDL and serves as a direct measure of HDL particle number, providing insight that HDL-cholesterol alone cannot deliver. HDL-cholesterol reflects the cholesterol cargo carried by HDL particles of varying size, whereas Apo A1 reflects particle count — each HDL particle carries exactly one Apo A1 molecule. This distinction matters when HDL-cholesterol is discordant with risk, for instance when small dense HDL particles are numerous but carry little cholesterol, or when large lipid-rich HDL elevates cholesterol concentration without a proportionate particle increase. Practitioners order Apo A1 to refine cardiovascular risk assessment beyond the standard lipid panel, particularly in patients with metabolic syndrome, diabetes, or elevated triglycerides, and to calculate the ApoB:ApoA1 ratio, which encapsulates the balance between atherogenic and atheroprotective lipoproteins. It is also used in the evaluation of suspected familial hypoalphalipoproteinaemia and in monitoring lipid-modifying therapy when HDL response is a target.
What does the Apo A1 test measure?
Apolipoprotein A1 is the principal structural and functional protein of high-density lipoprotein particles. Synthesised predominantly in the liver and intestine, it accounts for roughly 70% of HDL protein mass and serves as a cofactor for lecithin-cholesterol acyltransferase, the enzyme that esterifies free cholesterol on the HDL surface and drives reverse cholesterol transport. Apo A1 also stabilises the HDL particle, binds cell-surface receptors that mediate cholesterol efflux, and exhibits anti-inflammatory and antioxidant properties within the arterial wall.
Apo A1 concentration reflects the number of circulating HDL particles and is a marker of reverse cholesterol transport capacity. Low Apo A1 predicts increased cardiovascular risk independently of HDL-cholesterol, particularly in settings where HDL-cholesterol and particle number diverge — such as hypertriglyceridaemia or metabolic syndrome. Apo A1 is also used to calculate the ApoB:ApoA1 ratio, a lipoprotein balance metric that can outperform traditional lipid ratios in risk stratification.
Why is the Apo A1 test ordered?
- Cardiovascular risk stratification in patients with metabolic syndrome, type 2 diabetes, or chronic kidney disease where HDL-cholesterol may underestimate or overestimate protective capacity
- Evaluation of persistently low HDL-cholesterol to distinguish true particle deficiency from measurement artefact or altered particle composition
- Calculation of the ApoB:ApoA1 ratio for atherogenic lipoprotein balance assessment, particularly when LDL-cholesterol and non-HDL-cholesterol are discordant with triglycerides
- Investigation of suspected familial hypoalphalipoproteinaemia or other genetic HDL disorders in patients with very low HDL-cholesterol and a family history of premature coronary disease
- Monitoring response to lifestyle modification, lipid-lowering therapy, or emerging HDL-targeted treatments where changes in particle number are of interest
- Risk assessment in patients with elevated lipoprotein(a) or other residual risk factors despite well-controlled LDL-cholesterol
- Clarification of cardiovascular risk in women, in whom HDL-cholesterol has stronger predictive power and Apo A1 can add discrimination
Sample collection and turnaround
Sample type
Blood (serum)
Fasting required
Preferred
Collection method
Venipuncture at patient service centre
Turnaround
2–3 business days
Collection notes
Phlebotomy via Quest; fasting for 9–12 hours is preferred for consistency and to minimise postprandial lipoprotein effects, particularly when the ApoB:ApoA1 ratio is calculated. Avoid testing during acute illness or within two weeks of myocardial infarction, surgery, or infection.
Specimen requirements
Minimum 0.5 mL serum. Separate from cells within two hours; Apo A1 is stable refrigerated for up to one week and frozen for longer storage. Avoid haemolysed specimens.
What can affect Apo A1 results?
Apo A1 is a negative acute-phase reactant; levels fall during systemic inflammation, sepsis, and acute coronary syndromes, so testing during acute illness underestimates baseline values.
Metabolic syndrome and visceral adiposity lower Apo A1 synthesis and accelerate HDL catabolism, reducing both concentration and reverse cholesterol transport capacity.
Exogenous oestrogen and physiological pregnancy raise Apo A1 and HDL-cholesterol, so testing should ideally reflect the patient's chronic hormonal state for risk assessment.
Moderate alcohol intake increases Apo A1 and HDL-cholesterol; heavy drinking may also elevate levels but introduces confounding cardiovascular and hepatic effects.
Apo A1 is less affected by postprandial changes than triglycerides or ApoB, but fasting samples are preferred for consistency, particularly when the ApoB:ApoA1 ratio is calculated.
Advanced renal disease and heavy proteinuria alter HDL metabolism unpredictably, sometimes lowering Apo A1 and impairing HDL function despite normal or elevated HDL-cholesterol.
What do Apo A1 results mean?
Elevated
High Apo A1 is generally favourable and associated with reduced cardiovascular risk, though extreme elevations do not confer additional benefit and may reflect genetic variants such as CETP deficiency. Modest increases are seen with alcohol consumption, oestrogen therapy, and some lipid-modifying drugs. Elevated Apo A1 does not exclude cardiovascular disease if atherogenic lipoproteins are also raised.
Normal
Apo A1 within the reference range indicates a normal circulating HDL particle mass but does not guarantee functional reverse cholesterol transport or exclude cardiovascular risk. Interpretation must integrate the entire lipid panel, ApoB, inflammatory markers, and clinical context — normal Apo A1 with elevated ApoB still represents an unfavourable balance.
Reduced
Low Apo A1 signals reduced HDL particle number and impaired reverse cholesterol transport, and predicts increased cardiovascular risk. Common causes include metabolic syndrome, type 2 diabetes, obesity, smoking, and sedentary lifestyle; rare genetic disorders such as familial hypoalphalipoproteinaemia, apoA1 mutations, and Tangier disease also present with very low concentrations. Low Apo A1 with normal or near-normal HDL-cholesterol suggests small lipid-poor HDL particles and merits further investigation.
Note: Apo A1 is most informative when interpreted alongside ApoB and the ApoB:ApoA1 ratio; reference ranges vary by sex, age, ethnicity, and assay method. It is a negative acute-phase reactant, so avoid testing during acute illness. Serial measurements should use the same laboratory and methodology for comparability, and functional HDL assays may add insight when particle number and cholesterol efflux capacity diverge.
Frequently asked questions
Apo A1 measures the number of HDL particles (each carries one Apo A1 molecule), while HDL-cholesterol measures the cholesterol cargo they carry. The two can diverge when particle size or lipid content changes, and Apo A1 often predicts cardiovascular risk more reliably, especially in metabolic syndrome and diabetes.
How to access the Apo A1 test
The Apo A1 reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: October 7, 2026
Last reviewed: October 7, 2026
- Sniderman AD, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. (2019)
- Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy — a review of the evidence. J Intern Med. (2006)
- European Association for Cardiovascular Prevention & Rehabilitation; ESC Committee for Practice Guidelines. ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. (2019)
- Mora S, et al. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation. (2014)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.
Related tests
cardiovascular
Apo-B
The Apolipoprotein B (Apo-B) test counts the total number of atherogenic lipoprotein particles, since each LDL, VLDL, IDL, and lipoprotein(a) particle carries one apolipoprotein B. It is a strong cardiovascular risk marker, in many analyses superior to LDL cholesterol because it captures particle number rather than cholesterol content, and is especially informative where LDL cholesterol…
cardiovascular
HDL-C
The HDL cholesterol test measures the cholesterol carried within high-density lipoprotein particles, a core component of the lipid profile and cardiovascular risk assessment. Low HDL-C is an independent risk marker, but HDL-C reflects cholesterol concentration rather than HDL function and is a risk marker, not a validated treatment target;
cardiovascular
Lipid Panel
The Lipid Panel measures total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, non-HDL cholesterol, and VLDL cholesterol from a single fasting serum specimen, providing the foundational cardiovascular lipid risk profile for ASCVD risk stratification, lipid-lowering therapy initiation and monitoring, familial hypercholesterolaemia identification, and atherogenic dyslipidaemia…